TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TScan Therapeutics (TCRX) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing a weak technical setup, no strong proprietary buy signal, and no recent news catalyst to support an immediate entry. Given the lack of a clear bullish trend and the absence of SwingMax or AI Stock Picker support, I would avoid buying now and wait for a stronger setup.
The chart setup is bearish overall. MACD histogram is slightly negative and still below zero, though contracting, which suggests downside momentum is easing but not yet reversed. RSI_6 at 53.4 is neutral, so there is no oversold rebound signal or strong bullish momentum. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock remains in a longer-term downtrend. Price at 1.08 is sitting just above pivot 1.049, with immediate resistance at 1.129 and stronger resistance at 1.178. Support is 0.97, then 0.92. The short-term trend model also points modestly negative over the week and month, reinforcing a weak near-term setup.
Hedge funds are buying aggressively; Wedbush raised PT and kept Outperform; future Phase 1 ALLOHA trial results/update could act as a catalyst.
Bearish moving averages; MACD below zero; no recent news; no AI Stock Picker signal; no SwingMax signal; neutral insider activity; no congress trading data; short-term trend model is slightly negative.
No financial snapshot was available due to an error, so latest-quarter revenue, earnings, and growth trends cannot be assessed from the provided data.
Recent analyst sentiment is positive: Wedbush raised the price target to $5 from $4 and maintained an Outperform rating on 2026-03-05. That implies improving Street confidence, but it is a single recent upgrade rather than broad consensus evidence. Wall Street pros: higher target, Outperform, and anticipation of future trial updates. Wall Street cons: no recent news momentum, no confirmed technical reversal, and no proprietary buy signal today.
